Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012373 | 0.83 | ALDH1A1 (0.40) | MEN1KMT2A | |
| SCHEMBL1011779 | 0.74 | USP30 (0.52) | USP30NAMPTKMT2APOLR1A | |
| SCHEMBL23830839 | 0.74 | USP30 (0.52) | USP30NAMPTRORCMEN1KMT2A | |
| SCHEMBL1010049 | 0.73 | HDAC3 (0.52) | NAMPTPOLR1ATACR1SSTR4 | |
| SCHEMBL22728591 | 0.72 | PDE10A (0.51) | NAMPTGPR119PDE10A | |
| SCHEMBL27091311 | 0.72 | USP30 (0.54) | USP30NAMPTRORCMEN1KMT2A | |
| SCHEMBL23719680 | 0.72 | NR1H2 (0.49) | USP30NAMPTRORCMEN1KMT2A | |
| SCHEMBL23700613 | 0.72 | NR1H2 (0.49) | USP30NAMPTRORCMEN1KMT2A | |
| SCHEMBL28506418 | 0.72 | NR1H2 (0.49) | USP30NAMPTRORCMEN1KMT2A | |
| SCHEMBL23700614 | 0.72 | NR1H2 (0.49) | USP30NAMPTRORCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1881977-A1 | HISTONE DEACETYLASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | USP30 1578/4885NAMPT 582/4885RORC 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.